1. Academic Validation
  2. Oncogenic RAS-Induced Perinuclear Signaling Complexes Requiring KSR1 Regulate Signal Transmission to Downstream Targets

Oncogenic RAS-Induced Perinuclear Signaling Complexes Requiring KSR1 Regulate Signal Transmission to Downstream Targets

  • Cancer Res. 2018 Feb 15;78(4):891-908. doi: 10.1158/0008-5472.CAN-17-2353.
Sandip K Basu 1 Sook Lee 1 Jacqueline Salotti 1 Srikanta Basu 1 Krisada Sakchaisri 1 Zhen Xiao 2 Vijay Walia 3 Christopher J Westlake 3 Deborah K Morrison 3 Peter F Johnson 4
Affiliations

Affiliations

  • 1 Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland.
  • 2 Laboratory of Proteomics and Analytical Technologies, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • 3 Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, Maryland.
  • 4 Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland. [email protected].
Abstract

The precise characteristics that distinguish normal and oncogenic Ras signaling remain obscure. Here, we show that oncogenic Ras and BRaf induce perinuclear relocalization of several Ras pathway proteins, including the kinases CK2 and p-ERK1/2 and the signaling scaffold KSR1. This spatial reorganization requires endocytosis, the kinase activities of MEK-ERK and CK2, and the presence of KSR1. CK2α colocalizes with KSR1 and Rab11, a marker of recycling endosomes, whereas p-ERK associates predominantly with a distinct KSR1-positive endosomal population. Notably, these perinuclear signaling complexes (PSC) are present in tumor cell lines, mouse lung tumors, and mouse embryonic fibroblasts undergoing RAS-induced senescence. PSCs are also transiently induced by growth factors (GF) in nontransformed cells with delayed kinetics (4-6 hours), establishing a novel late phase of GF signaling that appears to be constitutively activated in tumor cells. PSCs provide an essential platform for RAS-induced phosphorylation and activation of the prosenescence transcription factor C/EBPβ in primary MEFs undergoing senescence. Conversely, in tumor cells, C/EBPβ activation is suppressed by 3'UTR-mediated localization of Cebpb transcripts to a peripheral cytoplasmic domain distinct from the PSC region. Collectively, our findings indicate that sustained PSC formation is a critical feature of oncogenic Ras/BRaf signaling in Cancer cells that controls signal transmission to downstream targets by regulating selective access of effector kinases to substrates such as C/EBPβ.Significance: In addressing the long-standing question of the difference between normal and oncogenic Ras pathway signaling, this study shows that oncogenic Ras specifically triggers constitutive endocytosis-dependent movement of effector kinases to a perinuclear region, thereby creating connections to unique downstream targets such as the core prosenescence and the inflammatory regulatory transcription factor C/EBPβ. Cancer Res; 78(4); 891-908. ©2017 AACR.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-50846
    99.27%, ERK1/2 Inhibitor
    ERK